Spencer Feldman

Avoiding surgery and utilizing the “wait-and-watch” approach may be beneficial in certain patients with locally advanced rectal cancer. Among patients with locally advanced rectal cancer who were treated with total neoadjuvant therapy and whose doctors continue to monitor for signs […]

Combination therapy of Lenvima with Ipex and Vepesid missed its goal of improved progression-free survival for children with relapsed or refractory osteosarcoma. Among children and young adults with relapsed or refractory osteosarcoma, the combination of Lenvima (lenvatinib) to Ipex (ifosfamide)

Partial nephrectomy may improve overall and cancer-specific survival rates compared to radiofrequency ablation for patients with cT1a renal cell carcinoma. Partial nephrectomy (PN) demonstrated similar overall survival and cancer-specific survival in patients with cT1a renal cell carcinoma (RCC) compared with

The FDA has accepted a biologics license application for a Blenrep regimen for patients with relapsed or refractory multiple myeloma. The Food and Drug Administration (FDA) accepted a biologics license application (BLA) for Blenrep(belantamab mafodotin) in combination with bortezomib plus

Truqap combo showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. Among patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, Truqap (capivasertib) combined with Zytiga (abiraterone acetate) and androgen deprivation therapy

An Itovebi regimen demonstrated survival benefits for patients with HR-positive, HER2-negative metastatic breast cancer. Among patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic (spreading) breast cancer, Itovebi (inavolisib) plus Ibrance (palbociclib) with Faslodex (fulvestrant) led to significantly

Adjuvant Opdivo improved overall and disease-free survival for patients with high-risk muscle-invasive urothelial cancer after radical resection. Recently published findings support adjuvant Opdivo (nivolumab) as a standard of care for high-risk muscle-invasive urothelial cancer, a type of bladder cancer, following

In patients ineligible for platinum-based chemotherapy with advanced bladder cancer, initial Keytruda may be important. Among patients with advanced bladder carcinoma who are potentially ineligible for platinum-based chemotherapy, initial treatment with Keytruda has consistent antitumor activity and safety, regardless of

While aerobic exercise improved self-reported cognitive function and quality of life in women undergoing chemotherapy for breast cancer, it had no significant impact on objective cognitive function post-treatment. The use of aerobic exercise demonstrated improved self-reported cognitive function and its

Newer treatments for patients with acute lymphoblastic leukemia may offer the potential for fewer side effects than traditional chemotherapy, an expert said. These innovative therapies, including drugs like Besponsa (inotuzumab), glembatumumab and Blincyto (blinatumomab), target cancer cells more precisely, reducing